Long-Acting Anti-Influenza Monoclonal Antibody Platform Targets Immunocompromised Patients

Summary RQ Bio announced the successful completion of an oversubscribed $115 million Series A financing, led by Frazier Life Sciences, to advance its long-acting antibody platform for influenza prevention. The financing will support IND-enabling development of RQB01, a next-generation monoclonal antibody engineered to provide season-long…